MUMBAI (Reuters) - Drugmaker Cipla Ltd
The Mumbai-based company, India's fifth largest drugmaker by sales, said standalone net profit dropped to 2.68 billion rupees in the fiscal fourth quarter ended March compared to 2.92 billion rupees last year. Sales rose 5 percent to 19.06 billion rupees, it said.
Analysts, on an average, had estimated net profit at 3.25 billion rupees on sales of 20.86 billion rupees, according to Thomson Reuters I/B/E/S.
Valued $5.7 billion, shares in Cipla closed up 1.36 percent at 401.70 rupees on Wednesday, while the BSE Sensex fell 0.07 percent.
($1 = 55.92 rupees)
(Reporting by Kaustubh Kulkarni; Editing by Sunil Nair)